FOLH1 and prostate carcinoma: Regarding the overall incidence of PSMA-negativity in prostate cancer, Mannweiler et al. found 5% of primary prostate cancer and 15% of prostate cancer metastases to be PSMA-negative in immunohistochemistry [30].